Development Pipeline


MEMO is using the MemoMAB™ platform technology to develop a proprietary therapeutic antibody lead pipeline. The initial focus is on infectious diseases. The company also works on undisclosed targets in cancer and immune mediated inflammatory diseases (IMID).

In collaboration with clinical groups at the University Hospitals of Zurich and Basel, MEMO has embarked on the generation of human antibodyome libraries from clinically selected donors in the frame of non-interventional clinical studies.